PURPOSE OF REVIEW: Cardiac xenotransplantation (CXTx) remains a promising approach to alleviate the chronic shortage of donor hearts. This review summarizes recent results of heterotopic and orthotopic CXTx, highlights the role of non-Gal antibody in xenograft rejection, and discusses challenges to clinical orthotopic CXTx. RECENT FINDINGS: Pigs mutated in the α 1,3 galactosyltransferase gene (GTKO pigs) are devoid of the galactose α1,3 galactose (αGal) carbohydrate antigen. This situation effectively eliminates any role for anti-Gal antibody in GTKO cardiac xenograft rejection. Survival of heterotopic GTKO cardiac xenografts in nonhuman primates continues to increase. GTKO graft rejection commonly involves vascular antibody deposition and variable complement deposition. Non-Gal antibody responses to porcine antigens associated with inflammation, complement, and hemostatic regulation and to new carbohydrate antigens have been identified. Their contribution to rejection remains under investigation. Orthotopic CXTx is limited by early perioperative cardiac xenograft dysfunction (PCXD). However, hearts affected by PCXD recover full cardiac function and orthotopic survival up to 2 months without rejection has been reported. SUMMARY: CXTx remains a promising technology for treating end-stage cardiac failure. Genetic modification of the donor and refinement of immunosuppressive regimens have extended heterotopic cardiac xenograft survival from minutes to in excess of 8 months.
PURPOSE OF REVIEW: Cardiac xenotransplantation (CXTx) remains a promising approach to alleviate the chronic shortage of donor hearts. This review summarizes recent results of heterotopic and orthotopic CXTx, highlights the role of non-Gal antibody in xenograft rejection, and discusses challenges to clinical orthotopic CXTx. RECENT FINDINGS:Pigs mutated in the α 1,3 galactosyltransferase gene (GTKO pigs) are devoid of the galactose α1,3 galactose (αGal) carbohydrate antigen. This situation effectively eliminates any role for anti-Gal antibody in GTKO cardiac xenograft rejection. Survival of heterotopic GTKO cardiac xenografts in nonhuman primates continues to increase. GTKO graft rejection commonly involves vascular antibody deposition and variable complement deposition. Non-Gal antibody responses to porcine antigens associated with inflammation, complement, and hemostatic regulation and to new carbohydrate antigens have been identified. Their contribution to rejection remains under investigation. Orthotopic CXTx is limited by early perioperative cardiac xenograft dysfunction (PCXD). However, hearts affected by PCXD recover full cardiac function and orthotopic survival up to 2 months without rejection has been reported. SUMMARY:CXTx remains a promising technology for treating end-stage cardiac failure. Genetic modification of the donor and refinement of immunosuppressive regimens have extended heterotopic cardiac xenograft survival from minutes to in excess of 8 months.
Authors: P P M Rood; H Hara; M Ezzelarab; J Busch; X Zhu; Z Ibrahim; S Ball; D Ayares; M Awwad; D K C Cooper Journal: Transplant Proc Date: 2005-10 Impact factor: 1.066
Authors: Guerard W Byrne; Paul G Stalboerger; Zeji Du; Tessa R Davis; Christopher G A McGregor Journal: Transplantation Date: 2011-02-15 Impact factor: 4.939
Authors: Carol J Phelps; Chihiro Koike; Todd D Vaught; Jeremy Boone; Kevin D Wells; Shu-Hung Chen; Suyapa Ball; Susan M Specht; Irina A Polejaeva; Jeff A Monahan; Pete M Jobst; Sugandha B Sharma; Ashley E Lamborn; Amy S Garst; Marilyn Moore; Anthony J Demetris; William A Rudert; Rita Bottino; Suzanne Bertera; Massimo Trucco; Thomas E Starzl; Yifan Dai; David L Ayares Journal: Science Date: 2002-12-19 Impact factor: 47.728
Authors: A J Hing; A Watson; M Hicks; L Gao; S C Faddy; A C McMahon; S H Kesteven; M K Wilson; P Jansz; M P Feneley; P S Macdonald Journal: Am J Transplant Date: 2009-07-23 Impact factor: 8.086
Authors: Johannes M Schirmer; David N Fass; Guerard W Byrne; Henry D Tazelaar; John S Logan; Christopher G A McGregor Journal: Xenotransplantation Date: 2004-09 Impact factor: 3.907
Authors: Soad M Saleh; Ranjit S Parhar; Reem S Al-Hejailan; Razan H Bakheet; Hala S Khaleel; Hanif G Khalak; Anason S Halees; Marya Z Zaidi; Brian F Meyer; Gisella P Yung; Jörg D Seebach; Walter Conca; Khalid S Khabar; Kate S Collison; Futwan A Al-Mohanna Journal: J Immunol Date: 2013-07-19 Impact factor: 5.422
Authors: Alexander E Merkler; Monica L Chen; Neal S Parikh; Santosh B Murthy; Shadi Yaghi; Parag Goyal; Peter M Okin; Maria G Karas; Babak B Navi; Costantino Iadecola; Hooman Kamel Journal: Stroke Date: 2019-03 Impact factor: 7.914
Authors: L Burdorf; T Stoddard; T Zhang; E Rybak; A Riner; C Avon; A Laaris; X Cheng; E Sievert; G Braileanu; A Newton; C J Phelps; D Ayares; A M Azimzadeh; R N Pierson Journal: Am J Transplant Date: 2014-04-02 Impact factor: 8.086
Authors: Donald G Harris; Kevin J Quinn; Siamak Dahi; Lars Burdorf; Agnes M Azimzadeh; Richard N Pierson Journal: Xenotransplantation Date: 2014-07-05 Impact factor: 3.907
Authors: Hayato Iwase; Burcin Ekser; Vikas Satyananda; Mohamed Ezzelarab; David K C Cooper Journal: Xenotransplantation Date: 2014-07-08 Impact factor: 3.907
Authors: Hayato Iwase; Burcin Ekser; Hidetaka Hara; Mohamed B Ezzelarab; Cassandra Long; Angus W Thomson; David Ayares; David K C Cooper Journal: Xenotransplantation Date: 2016-07-04 Impact factor: 3.907